Tango Therapeutics
TNGX· Manufacturing· Fiscal year ends in December
No proxy on file names the CEO of Tango Therapeutics.
Executives3
See all- 1Barbara Weber, M.D.Executive ChairmanFY2025
- 2Adam Crystal, M.D., Ph.D.President of Research and DevelopmentFY2025
- 3Daniella BeckmanFormer Chief Financial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allTango Therapeutics paid its 3 named executives $5.7M in total in FY2025 (Dec).
| Name | |||
|---|---|---|---|
| Barbara Weber, M.D.Executive Chairman | |||
| Adam Crystal, M.D., Ph.D.President of Research and Development | |||
| Daniella BeckmanFormer Chief Financial Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers18
See allThe comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board2
See all- Lesley Ann CalhounDirector · 4 yr on the boardIndependentAudit (Chair), Nominating and Corporate Governance—Paid as an executive
- Sung LeeDirector · -1 yr on the boardIndependentAudit—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 17, 2026 | FY2025 |
| Annual report | 10-K | Mar 5, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 21, 2025 | FY2024 |
| Annual report | 10-K | Feb 27, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 29, 2024 | FY2023 |
| Annual report | 10-K | Mar 18, 2024 | FY2023 |